Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trialMehreen S. Datoo, Halidou Tinto, Jenny M. Reimer et al.|The Lancet|2021Cited by 457
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trialMehreen S. Datoo, Halidou Tinto, Hamtandi Magloire Natama et al.|The Lancet Infectious Diseases|2022Cited by 285
Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional studyStuart A. Ali, Michèle Ramsay, Cassandra Claire Soo et al.|Global Health Action|2018Cited by 146
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling studyNora Schmit, Peter Winskill, Hillary M. Topazian et al.|The Lancet Infectious Diseases|2024Cited by 48
Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort studyHamtandi Magloire Natama, Anna Rosanas‐Urgell, Eduard Rovira-Vallbona et al.|Malaria Journal|2018Cited by 47